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Abstract
Introduction: Diagnosis of antiphospholipid syndrome (APS) still remains a laboratory challenge due to the great
diversity of antiphospholipid antibodies (aPL) and their significance regarding APS-diagnostic criteria.
Methods: A multi-line dot assay (MLDA) employing phosphatidylserine (PS), phosphatidylinositol (PI), cardiolipin
(CL), and beta2-glycoprotein I (b2 GPI) was used to detect aPL, immunoglobulin G (IgG) and immunoglobulin M
(IgM) in 85 APS patients, 65 disease controls, and 79 blood donors. For comparison, anti-CL and anti-b2 GPI IgG
and IgM were detected by enzyme-linked immunosorbent assay (ELISA).
Results: The level of agreement of both methods was good for anti-CL IgG, moderate for anti-CL IgM, very good for
anti-b2 GPI IgG, and moderate for anti-b2 GPI IgM (kappa = 0.641, 0.507, 0.803 and 0.506, respectively). The frequency
of observed discrepancies for anti-CL IgG (1.75%), anti-CL IgM (3.93%), anti-b2 GPI IgG (1.75%), and anti-b2 GPI IgM
(0.87%) was low (McNemar test, P < 0.05, not-significant, respectively). Sensitivity, specificity, positive (+LR) and
negative (-LR) likelihood ratios for at least one positive aPL antibody assessed by ELISA were 58.8%, 95.8%, 14.1, and
0.4, respectively, and for at least three positive aPl IgM and/or one positive aPL IgG by MLDA were 67.1%, 96.5%, 19.3,
and 0.3, respectively. The frequency of IgM to PI, PS and CL, and combination of three or more aPL IgM detected by
MLDA was significantly higher in APS patients with cerebral transient ischemia (P < 0.05, respectively).
Conclusions: The novel MLDA is a readily available, single-step, sensitive diagnostic tool for the multiplex
detection of aPL antibodies in APS and a potential alternative for single aPL antibody testing by ELISA.
Introduction
Antiphospholipid syndrome is an autoimmune clinical
entity comprising as core manifestations venous or arter-
ial thrombosis and recurrent fetal loss [1-3]. The APS
can occur primary in isolation or secondary in associa-
tion with other autoimmune conditions, notably systemic
lupus erythematosus (SLE). The most life threatening
manifestation of APS is called catastrophic APS charac-
terized by multi-organ failure due to occlusion of small
blood vessels [4]. According to a recently updated inter-
national consensus statement, the association of at least
one clinical criterion with one laboratory criterion deter-
mines the diagnosis of APS. Persistent elevation of aPL
antibodies and/or lupus anticoagulant over 12 weeks
constitutes the diagnostic criterion [5]. The generic term
aPL antibodies comprises antibodies that interact with
phospholipids directly and particularly those that target
cofactor proteins binding to such phospholipids. Anti-
phospholipid antibodies that interfere with phospholipid-
dependent steps in the coagulation cascade constitute the
lupus anticoagulant (LAC) determined by functional clot-
ting tests. Antiphospholipid antibodies reacting with pure
phospholipids alone appear to belong to the natural anti-
body repertoire and may be elevated during certain infec-
tions [6,7]. In fact, such aPL antibodies to CL, PI,
phosphatidylcholine and PS have been demonstrated in
APS patients and appear to be relevant for the laboratory
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cofactor proteins in complex with phospholipids have
been reported to have a closer association with clinical
manifestations in APS [8-13].
Consequently, aPL antibodies have been shown to be a
rather heterogeneous group with distinct associations
with clinical symptoms of APS. Therefore, despite the
revised APS consensus criteria, diagnosis of APS
remains challenging [14]. According to the updated con-
sensus statement, anti-b2 GPI and anti-CL IgG and IgM
antibodies and LAC are recommended for aPL antibody
testing [5]. In case of seronegativity of these aPL antibo-
dies and clinical signs consistent with APS, further aPL
should be assessed requiring laboratory flexibility and
appropriate tests. With regard to the detection techni-
ques applied, antiphospholipid antibodies have been
mainly detected by solid-phase ELISA so far.
Thus, state-of-the art laboratory diagnosis of APS
requires running several ELISA simultaneously in routine
laboratories, which generates substantial costs. There is
clearly a need for multiplex tests detecting aPL antibo-
dies. Multi-line dot assays or other multiplex techniques
like biosensor analysis may overcome this shortcoming
by providing the opportunity to detect several aPL anti-
bodies simultaneously as reported for multiplex assess-
ment of autoantibodies in other autoimmune diseases
like SLE [15,16].
In this study, we demonstrated the practicability of a
unique multi-line dot technique for simultaneous determi-
nation of aPL antibodies against four different targets. The
objective of the study was to investigate the hypothesis
whether this assay technique would be an alternative for
aPL antibody testing in the serological diagnosis of APS.
By providing reliable results, this new approach would be
cost-effective and time-saving compared to single detec-
tion of aPL antibodies.
Methods
Patients and controls
Eighty-five patients with APS (71 females, 14 males, med-
ian age 45 years, range 16 to 77 years) were included in
this study. Diagnosis of APS had been established by char-
acteristic clinical and serological criteria according to the
international consensus criteria [5]. Eight (9.4%) of the 85
patients with APS suffered from adverse outcomes in
pregnancy, whereas 62 (72.9%) had a history of arterial
and/or venous thrombosis. Fifty-seven (67.1%) of the latter
suffered from deep venous thrombosis (DVT). Eighteen
(21.2%) of the patients suffering from APS met the diag-
nostic criteria for SLE. Thirteen (15.3%) APS patients
demonstrated cerebral transient ischemic attack (TIA)
(10/85) and/or ischemic stroke (5/85). Two APS patients
each with thrombotic events suffered from Sjögren’s syn-
drome and scleroderma, respectively. One APS patient
with thrombotic events suffered from rheumatoid arthritis
and two patients from spondyloarthropathies.
As a disease control group of patients suffering from dis-
eases unrelated to APS (DC), sera of 65 patients with clini-
cal symptoms suspicious of APS but without positive
laboratory tests were included (60 females, 5 males; med-
ian age: 46 years, range 19 to 76 years). Ten (15.4%) of
those 65 patients suffered from recurrent abortions unre-
lated to APS and 17 (26.2%) demonstrated DVT of non-
APS causes. Five (7.7%) APS patients demonstrated TIA
and one patient had an ischemic stroke. Four patients
from this group were diagnosed with undifferentiated con-
nective tissue disease, three patients met the diagnostic
criteria for SLE, four patients for Sjögren’s syndrome, and
one patient for scleroderma. Complete physical examina-
tions had been performed in all patients with APS and
controls by one investigator (TD).
As controls, 79 sera from normal healthy subjects
(NHS), anonymous age- and sex matched donors were
used.
The study was approved by the local ethical committee
(EA1/001/06). Written informed consent was obtained
from each patient. All sera had been stored at -20°C.
Monoclonal anti-phospholipid antibodies
For comparison of ELISA and MLDA detection of aPL,
the human monoclonal antibody (mAb) EY2C9 (IgM)
reacting against epitopes on b2GPI was obtained from the
Center of Disease Control. In the presence of b2G P I ,
EY2C9 bound to CL coated plates.
Furthermore, the human monoclonal IgG antibodies
HL5B and HL7G, generated from a patient with primary
APS and recurrent cerebral microemboli, were included
[17,18]. Both antibodies are of the IgG2 subtype with
lambda light chains; however, they differ in their aPL
reactivity.
Assessment of lupus anticoagulant by phospholipid-
dependent coagulation test
Lupus anticoagulant (LAC) was detected according to
the guidelines of the International Society on Thrombo-
sis and Haemostasis [19].
ELISA for the detection of antibodies to cardiolipin and
b2 GPI
Antibodies to CL and b2 GPI in the patient sera were
detected using commercially available solid-phase ELISA
employing purified CL and b2 GPI in complex with car-
diolipin as solid-phase antigens, respectively (GA Generic
Assays GmbH, Dahlewitz, Germany). Assessment of aPL
antibodies was conducted according to the instructions
of the manufacturer. Sera were considered positive when
their concentration exceeded the cut-off of 10 GPU or
MPU for IgG and IgM respectively.
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Antibodies to CL, b2 GPI, PS, and PI in the patient sera
were detected using a commercially available MLDA
employing purified human b2 GPI (The Binding Site, Bir-
mingham, UK) and phospholipids according to the
recommendations of the manufacturer (GA Generic
Assays GmbH, Dahlewitz, Germany). Briefly, the phos-
pholipids CL, PS, and PI (Sigma, Taufkirchen, Germany)
and the protein b2 GPI were sprayed onto (polyvinyli-
dene difluoride) PVDF membrane in lines for immobili-
zation as described for glycolipids recently [20] Processed
strips were read out densitometrically employing a scan-
ner with the evaluation software Dot Blot Analyzer
(Additional file, Figure S1, GA Generic Assays GmbH,
Dahlewitz, Germany).
Statistical analysis and determination of assay
performance characteristics
Intra- and inter-assay coefficients of variations (CV) were
calculated. The functional assay sensitivity for aPL detec-
tion was determined as described previously [21]. Differ-
ences between groups were tested by chi-square test and
Fisher’s exact test with two-tailed probability as appropri-
ate. Inter-rater agreement statistics was applied for within
group comparison. P-values < 0.05 were considered signifi-
cant. Assay performance including sensitivity, specificity,
positive and negative likelihood ratio and receiver-operat-
ing characteristics (ROC) curve analysis were determined
using Medcalc statistical software (Medcalc, Mariakerke,
Belgium).
Results
Characterisation of the multi-line dot assay
Assay performance analysis of ELISA and MDLA demon-
strated similar data regarding assay variation and func-
tional assay sensitivity. Data are shown in Additional file 1.
For comparison of ELISA and MLDA techniques, the
h u m a nm A bI g GH L 7 Ga n dH L 5 B ,a n dt h eh u m a nI g M
EY2C9 were run in anti-CL and anti-b2 GPI ELISAs and
in the novel MLDA. The latter mAb obtained from the
Center of Disease Control reacted readily in both anti-CL
and anti-b2 GPI IgM ELISAs and demonstrated a strong
IgM reactivity to b2 GPI in the MLDA. The level of aPL
specific IgM required to reach the cut-offs in the respec-
tive ELISAs were similar to the concentration of specific
IgM revealing a cut-off band in MLDA. In contrast, the
aPL IgG mAb HL7G and HL5B demonstrated reactivity in
MLDA only.
Profiling of aPL antibodies by ELISA and MLDA
Furthermore, sera from patients with APS (n = 85), DC
(n = 65), and NHS as controls (n = 79) were assessed
for comparison of aPL antibody in ELISA and the novel
MLDA (Table 1).
Patients suffering from APS demonstrated a significantly
higher frequency of anti-CL IgG (P < 0.000001, respec-
tively), anti-CL IgM (ELISA: P < 0.000001, respectively;
MLDA: P < 0.000001, P = 0.0002, respectively), anti-b2
GPI IgG (P < 0.000001, respectively) and anti-b2 GPI IgM
(ELISA: P < 0.000001, respectively; MLDA: P < 0.000001,
P = 0.000049, respectively) compared to DC patients and
NHS in both ELISA and MLDA. Anti-PS IgG and IgM
detected by MLDA occurred significantly more frequently
in patients with APS compared to the control groups (P <
0.000001, respectively and P = 0.000001, P = 0.000077,
respectively). The number of anti-PI IgG positive patients
was significantly elevated in the APS group in contrast to
DC patients and NHS (P = 0.004573, P = 0.014091,
respectively), whereas anti-PI IgM did not demonstrate a
significant higher prevalence in this patient cohort in com-
parison with the control groups.
Remarkably, all anti-PI positive samples found in the
APS patient cohort also showed a positive reactivity with
the respective anti-PS isotype antibody. Furthermore, all
anti-PS positive samples showed a positive anti-CL isotype
antibody response, too. Regarding aPL IgG positive APS
patients, all seven anti-PI IgG positive patients demon-
strated positive anti-PS, anti-CL, and anti-b2 GPI IgG by
MDLA either (P = 0.000447). Twenty (95.2%) of the
remaining 21 anti-PS IgG positive APS patients revealed a
similar pattern of positive anti-CL and anti-b2 GPI IgG by
MDLA, while only one patient showed anti-CL IgG only
(P < 0.000001). The two anti-PS IgG positive individuals
in the control groups demonstrated anti-CL IgG only.
Comparing ELISA and MLDA data, there was no statis-
tical difference in the frequencies of positive anti-CL and
anti-b2 GPI IgG antbodies detected by either method
(Table 2). The agreement between both methods was
assessed as good for anti-CL IgG (kappa = 0.641, 95% con-
fidence interval (CI): 0.541 to 0.767), moderate for anti-
CL-IgM (kappa = 0.507, 95% CI: 0.357 to 0.657), very
good for anti-b2 GPI IgG (kappa = 0.803, 95% CI: 0.685 to
0.921) and moderate for anti-b2 GPI IgM (kappa = 0.506,
95% CI: 0.352 to 0.659) according to inter-rater agreement
statistics.
It should be noted that comparing LAC with combined
MDLA data in the group of patients with APS, there was
no statistical difference according to McNemar’s test (dif-
ference: 5.88%; 95% CI: -11.26% to 22.29%; P = 0.5677). In
terms of MLDA, patient samples were scored positive
when IgG or IgM antibodies to PI, PS, CL, or b2G P Iw e r e
detected above the cut-off for bands. Lupus anticoagulant
and MLDA data were significantly related (contingency
coefficient = 0.324, P = 0.0016). Strength of agreement
between both methods was fair (kappa = 0.303, 95% CI:
0.152 to 0.455).
Patients suffering from APS showed significantly more
multiple positive samples detected by ELISA (41/85)
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0/65, MLDA: 2/65, P < 0.000001, respectively) and NHS
(ELISA: 0/79, MLDA: 6/79, P < 0.000001, respectively)
(Additional file 1, Table S1). The frequency of multiple
positive samples detected in the APS patient cohort by
ELISA was not significantly different from the frequency
obtained by MLDA (P = 0.759115). Interestingly, the
MLDA detected a higher number of samples (39/85)
with three and more positive aPL in the APS patient
g r o u pc o m p a r e dt oE L I S A( 2 9 / 8 5 ) ;h o w e v e r ,t h i sd i f f e r -
ence was not significant.
By comparing both detection methods in the DC
group, there was also no significant difference in the fre-
quency of multiple positive samples (P = 0.496124). In
the NHS group; however, only the number of samples
demonstrating three or more positive aPL antibodies was
not significantly different (P = 1.0). There was only one
NHS demonstrating three aPL IgM antibodies (anti- b2
GPI, anti-CL, and anti-PS) simultaneously in the MLDA.
Assay performance of aPL detection by ELISA and MLDA
The assay performance characteristics for the respective
aPL detected by ELISA are summarized in Table 3. The
specificities for all four detected aPL antibodies were
remarkably high ranging from 97.2% (anti- b2G P II g M )
to 100.0% (anti- b2 GPI IgG). The most sensitive aPL
antibody assessed by ELISA was anti-CL IgG revealing a
sensitivity of 52.9%. Taking into account the laboratory
criteria for APS requiring at least one positive aPL anti-
body, combined ELISA data showed a sensitivity of 58.8%
with a specificity of 95.8%. This resulted in a +LR of 14.1
and a -LR of 0.4.
The MLDA performance characteristics are given in
Table 4. Specificities for the respective aPL antibodies
ranged from 93.8% (anti-CL IgM) to 100.0% (anti-PI IgG
and IgM, anti- b2 GPI IgG). The most sensitive aPL anti-
body assessed by MLDA was also anti-CL IgG revealing a
sensitivity of 45.9%. In contrast to the ELISA perfor-
mance, the combined assessment of aPL by the MLDA
Table 1 Number of aPL antibody positive sera investigating 85 APS patients, 65 DC patients, and 79 NHS in ELISA and
in the MLDA
ELISA MLDA ELISA or
MDLA
anti-CL anti-b2
GPI
anti-CL or anti-b2
GPI
anti-PS anti-PI anti-CL anti-b2
GPI
anti-PS, anti-PI, anti-CL or anti-
b2 GPI
IgG IgM IgG IgM IgG IgM IgG IgM IgG IgM IgG IgM
APS
n =
85
45 32 27 33 50 28 17 7 3 39 33 31 27 57 63
DC
n =
65
1100 1 10002303 7 8
NHS
n =
79
10 *04 5 110026 *05 8 1 2
* P < 0.05 for the comparison of ELISA and MLDA
APS, antiphospholipid syndrome; anti-b2 GPI, anti-beta2-glycoprotein I; anti-CL, anti-cardiolipin; anti-PI, anti-phosphatidylinositol; anti-PS, anti-phosphatidylserine;
DC, disease controls; ELISA, enzyme-linked immunosorbent immunoassay; MLDA, multi-line dot assay; NHS, normal healthy subjects.
Table 2 Comparison of anti-CL and anti-b2 GPI antibodies detected in ELISA and MLDA
anti-CL IgG MLDA anti-CL IgM MLDA
positive negative n positive negative n
ELISA positive 32 15 47 ELISA positive 22 11 33
negative 11 171 182 negative 20 176 196
n 43 186 229 n 42 187 229
anti-b2 GPI IgG MLDA anti-b2 GPI IgM MLDA
positive negative n positive negative n
ELISA positive 24 3 27 ELISA positive 21 16 37
negative 7 195 202 negative 14 178 192
n 31 198 229 n 35 194 229
Investigating 85 APS patients, 65 DC patients, and 79 NHS in ELISA and MDLA, no statistical difference could be detected for both techniques. According to the
McNemar test, differences for anti-CL IgG (1.75%, 95% CI: -2.97% to 6.05%), anti-CL IgM (3.93%, 95% CI: -1.25% to 8.33%), anti-b2 GPI IgG (1.75%, 95 CI: -1.33% to
3.78%), and anti- b2 GPI IgM (0.87%, 95% CI: -4.11% to 5.67%) were not significant (P = 0.5563, P = 0.1508, P = 0.3438, and P = 0.1508, respectively). anti-b2 GPI,
anti-beta2-glycoprotein I;
anti-CL, anti-cardiolipin; ELISA, enzyme-linked immunosorbent immunoassay; MLDA, multi-line dot assay.
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city of 89.6% (Table 5). This resulted in a low +LR of 6.5
and an acceptable -LR of 0.4. The moderate specificity of
the MLDA was in particular due to a significantly higher
number of false positive anti-CL IgM determined in the
DC and NHS (9/144) groups compared to the ELISA
data (1/144, P = 0.019742).
Optimal assay performance of MLDA regarding APS
diagnosis
False positive aPL IgM findings in control patients and
NHS in particular were the main cause of a lower specifi-
city compared with ELISA data. Consequently, by
increasing the cut-off for the number of positive aPL IgM
to three and considering each positive aPL IgG antibody,
the resulting specificity of 96.5% for the MLDA increased
to a similar value obtained in ELISA (Table 5). The
remarkable sensitivity of 67.1% for this approach was
only slightly lower compared to the sensitivity consider-
ing each single aPL antibody in the MLDA. This sensitiv-
ity, requiring at least three positive aPL IgM antibodies
and/or at least one positive aPL IgG, however, is still
higher compared to the value obtained by ELISA (58.8%)
considering at least one positive aPL antibody. The corre-
sponding +LR for the MLDA demonstrated a remarkable
increase to 19.3 with a -LR of 0.3 presenting the optimal
assay performance regarding the diagnosis of APS for all
approaches in this study cohort.
Clinical association of MLDA findings
Regarding the number of patients with clinical symp-
toms and additional disease in the cohort of APS
patients, 57/85 patients suffered from DVT and 18/85
patients fulfilled the diagnostic criteria of SLE, which
was significantly higher in comparison with the DC
group (17/65, P < 0.000001; 3/65, P = 0.003918; respec-
tively). In contrast, the number of patients suffering
from TIA and/or ischemic stroke (13/85) and recurrent
miscarriages (8/85) did not differ significantly to the DC
group (6/65, 10/65, respectively).
Assessing all aPL antibodies detected by ELISA and
MLDA, only anti-PI IgM (3/10), anti-PS IgM (5/10), and
anti-CL IgM (7/10) antibodies detected by the MLDA
demonstrated a significant higher prevalence in the APS
patients suffering from TIAs compared with the remaining
APS patients (0/75, P = 0.001215; 12/75, P = 0.024165; 26/
75, P = 0.041781; respectively). Interestingly, the detection
o ft h r e eo rm o r ea P LI g Ma n t i b o d i e sb yM L D Aa l s o
revealed a significant higher prevalence in this APS patient
cohort (5/10 vs 11/75; P = 0.018102). More detailed ana-
lyses of the 13 APS patients with ischemic stroke and/or
TIA also revealed a significant higher prevalence of anti-PI
IgM (3/13) and anti-CL IgM (9/13) antibodies compared
with the remaining APS patients (0/72, P = 0.002826;
24/72, P = 0.027352; respectively). Again, the detection of
three or more aPL IgM antibodies by MLDA demon-
strated a significant higher prevalence in this APS patient
group (6/13 vs 10/72, P = 0.01376).
Remarkably, the absence of anti-CL IgM in the eight
APS patients with pregnancy morbidity assessed by
ELISA was significantly different to its occurrence in the
remaining 77 APS patients (P = 0.022343). Only one
patient of this group demonstrated positive anti-CL IgM
assessed by MLDA alone and one patient anti- b2G P I
Table 3 Performance characteristics of ELISA for IgG and IgM to CL and b2GPI
Sensitivity 95% CI specificity 95% CI +LR 95% CI -LR 95% CI
anti-CL IgG 52.9 41.8 to 63.9 98.6 95.1 to 99.8 38.1 9.5 to 153.2 0.5 0.4 to 0.6
anti-CL IgM 37.6 27.4 to 48.8 99.3 96.2 to 100.0 54.2 7.5 to 309.6 0.6 0.5 to 0.7
anti-b2 GPI IgG 31.8 22.1 to 42.2 100.0 97.5 to 100.0 ∞ 0.7 0.6 to 0.8
anti-b2 GPI IgM 38.8 28.4 to 50.0 97.2 93.0 to 99.2 14.0 5.1 to 38.1 0.6 0.5 to 0.8
Investigating 85 APS patients, 65 DC patients, and 79 NHS, sensitivity, specificity, and likelihood ratios were calculated using a cut-off of 10 U/ml for all ELISA
anti-b2 GPI, anti-beta2-glycoprotein I; anti-CL, anti-cardiolipin; +LR, positive likelihood ratio; -LR, negative likelihood ratio.
Table 4 Performance characteristics of MLDA for IgG and IgM to PS, PI, CL, and b2GPI
Sensitivity 95% CI Specificity 95% CI +LR 95% CI -LR 95% CI
anti-PS IgG 32.9 23.1 to 44.0 98.6 95.1 to 99.8 23.7 5.8 to 97.1 0.7 0.6 to 0.8
anti-PS IgM 20.0 12.1 to 30.1 99.3 96.2 to 100.0 28.8 3.9 to 212.6 0.8 0.7 to 0.9
anti-PI IgG 8.2 3.4 to 16.2 100.0 97.5 to 100.0 ∞ 0.9 0.9 to 1.0
anti-PI IgM 3.5 0.7 to 10.0 100.0 97.5 to 100.0 ∞ 1.0 0.9 to 1.0
anti-CL IgG 45.9 35.0 to 57.0 97.2 93.0 to 99.3 16.5 6.1 to 44.6 0.6 0.5 to 0.7
anti-CL IgM 38.8 28.4 to 50.0 93.8 88.5 to 97.1 6.2 3.1 to 12.3 0.6 0.6 to 0.8
anti-b2 GPI IgG 36.5 26.7 to 47.6 100.0 97.5 to 100.0 ∞ 0.6 0.5 to 0.8
anti-b2 GPI IgM 31.8 22.1 to 42.8 94.4 89.4 to 97.6 5.7 2.7 to 12.1 0.7 0.6 to 0.8
Investigating 85 APS patients, 65 DC patients, and 79 NHS, sensitivity, specificity, and likelihood ratios were calculated.
anti-b2 GPI, anti-beta2-glycoprotein I; anti-CL, anti-cardiolipin; +LR, positive likelihood ratio; -LR, negative likelihood ratio.
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by both methods. All other aPL IgM antibodies assessed
by the MLDA were negative, whereby the absence of
anti-b2 GPI IgM detected by this technique almost
reached statistical significance (P = 0.051114).
The prevalence of LAC was significantly higher in the
18 patients with APS and SLE compared to the remain-
ing 67 APS patients without SLE (18/18 vs 44/67, P =
0.002159), which was not seen for any other aPL anti-
body investigated.
Discussion
According to the classification criteria for APS, the
laboratory testing of aPL antibodies play an essential role
in diagnosing APS in comparison with other diagnostic
criteria for autoimmune disorders and subsequently lead
to important treatment decisions [5,22]. In this context,
the clinical diagnosis of APS has to be confirmed by and
depends on appropriate laboratory diagnosis. Therefore,
screening for aPL antibodies is usually not recommended
to avoid false-positive laboratory diagnosis as with other
lab investigations [14].
In fact, assessment of aPL still remains a diagnostic
challenge regarding both immunological tests for direct
aPL antibody detection and indirect assessment, thereof,
by coagulation tests.
Apart from technical aspects and assay characteristic
performance, cost-effectiveness, and availability of robust
tests are required. Multiplex detection of aPL antibodies
by MLDA may address these issues and provide a reliable
tool for aPL antibody profiling suggested for other auto-
immune diseases like rheumatoid arthritis [15,23]. The
use of aPL antibody profiles according to the number
and type of positive aPL antibody is recommended and
may identify patients at higher risk, although standardiza-
tion of assays remains a challenge [5,24,25].
To the best of our knowledge, this study reports the
first MLDA for the detection of multiple aPL IgG and
IgM antibodies. Results obtained by this assay technique
were in good agreement with data obtained by ELISA
and demonstrated no statistical difference regarding the
laboratory diagnosis of APS. Enzyme-linked immunosor-
bent assays have been the main method used for the
detection of aPL antibodies due to obvious immuno-
chemical peculiarities. For example, microtiter plates
activated by gamma radiation provide the opportunity to
detect disease-specific anti-b2 GPI antibodies in the
absence of phospholipids [26,27]. However, dot blot
assays have also been used to determine disease-specific
anti-b2 GPI antibodies [28,29]. The PVDF membrane
employed in the MLDA investigated in this study appears
to induce the same conformational changes in the b2 GPI
polypeptide since no significant different frequencies of
both anti- b2 GPI IgG and IgM was found in APS
patients comparing both assay techniques. Interestingly,
the human mAb aPL IgG antibodies demonstrated an
even better reactivity in the MLDA compared to ELISA.
It should be noted that this study provides data consis-
tent with the conclusion that not all clinically relevant
aPL are only directed against proteins [6,30,31]. The
phospholipids employed in the MLDA for the detection
of aPL antibodies are immobilized in the absence of co-
factors like b2 GPI and the only source thereof could be
proteins from the patient samples analyzed. Despite the
significantly higher rate of false-positive anti-CL IgM
detected by MLDA in NHS compared with ELISA, all
other aPL frequencies assessed by MLDA in the respec-
tive cohorts were not significantly different from ELISA
data. In this context, the IgM detection systems com-
p a r e dt ot h eI g Gt e s t sm a yb ei n f l u e n c e db ys o m en a t u -
rally occurring antibodies, in particular among sera from
the NHS group. By increasing the cut-off for positivity to
at least three positive aPL IgM and/or one aPL IgG assay
performance of MLDA for the serological diagnosis of
APS demonstrated even better data than ELISA. The sen-
sitivity for APS reached a remarkable value of 67.1% with
a corresponding +LR of 19.3 which is similar to values
reported elsewhere [32].
Interestingly, apart from LAC for SLE, only aPL IgM
detected by MLDA revealed a significant association with
clinical symptoms in the 85 patients with APS. The
remarkable significantly higher prevalence of IgM to PI,
PS, and CL in APS patients suffering from TIA and of
IgM to PI and CL in APS patients with TIA and/or
ischemic stroke warrants further investigation. Several
reviews covered neurological symptoms in patients with
APS [33,34]. The association of aPL to pure phospholi-
pids has been shown in patients suffering from multiple
sclerosis to be elevated in acute phases vs. remission [35].
Indeed, ELISA data of this study did not demonstrate
Table 5 Comparison of the performance characteristics of ELISA and MLDAf
Sensitivity 95% CI specificity 95% CI +LR 95% CI -LR 95% CI
at least one aPL antibody by ELISA 58.8 47.6 to 69.4 95.8 91.1 to 98.5 14.1 6.3 to 31.5 0.4 0.3 to 0.6
at least one aPL antibody by MLDA 67.9 56.8 to 77.6 89.6 83.4 to 94.0 6.5 4.0 to 10.8 0.4 0.3 to 0.5
at least one aPL IgG or at least three aPL IgM by MLDA 67.1 56.0 to 76.9 96.5 92.1 to 98.9 19.3 8.1 to 46.3 0.3 0.2 to 0.5
Sensitivity, specificity and likelihood ratios were calculated using a cut-off of 10 U/ml for all ELISA investigating 85 APS patients, 65 DC patients, and 79 NHS.
anti-b2 GPI, anti-beta2-glycoprotein I; anti-CL, anti-cardiolipin; aPL, anti-phospholipid antibody; ELISA, enzyme-linked immunosorbent immunoassay; MLDA, multi-
line dot assay; +LR, positive likelihood ratio; -LR, negative likelihood ratio.
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APS patients apart from the significant absence of anti-
CL IgM in APS patients with pregnancy morbidity.
Neither did anti-b2 GPI antibodies detected by both
techniques. These data may support the importance of
testing for aPL antibodies to pure phospholipids as
required by Nash et al, demonstrating that omitting the
classical anti-CL antibody assay caused 25% of APS
patients to be assessed as false-negative [36].
Remarkably, the appearance of aPL IgG antibodies to
pure anionic phospholipids detected by MLDA seems to
follow a particular pattern in patients with APS. The less
frequently found anti-PI IgG antibodies were always
accompanied by anti-PS, anti-CL, and anti-b2G P II g G .
Likewise, anti-PS IgG occurred at significantly higher fre-
quencies together with anti-CL and anti- b2 GPI IgG sug-
gesting a potential epitope spreading of aPL IgG from CL
to PS and further PI with the involvement of b2 GPI reac-
tivity. Interestingly, this phenomenon was not consistently
observed for aPL IgM. Whether this epitope spreading
seen for aPL IgG is confined to the anionic phospholipids
employed in the present MLDA only or covers other
phospholipid targets like phosphatidylethanolamin
remains to be investigated in further studies [37].
Conclusions
The MLDA technique appears to be an alternative to
ELISA for aPL antibody detection in the serological
diagnosis of APS. Multiplex detection of aPL antibodies
employing membrane surfaces as solid-phase for the
antigen immobilization provides the opportunity to
develop tests with higher numbers of aPL antibodies
improving the still challenging serological diagnosis of
APS. IgM antibodies to phospholipids detected by
MLDA demonstrate a significant association with cere-
brovascular events in APS.
Additional material
Additional file 1: Characterization of the multi-line dot assay in
comparison with ELISA. For evaluation of assay performance, CVs were
determined for the four ELISA and the aPL antibody reactivities assessed
by MLDA. The anti-CL IgG and IgM ELISAs displayed intra-assay variability
ranging from 2.3% to 4.1% and inter-assay variability ranging from 7.4%
to 10.3%. The anti- b2 GPI IgG and IgM ELISAs revealed intra-assay
variability from 3.3% to 4.5% and inter-assay variability from 5.2% to 6.1%.
The intra-assay CVs for a serum reactive with PI, PS, CL, and b2 GPI in the
MLDA were 5.2%, 6.8%, 8.3%, and 3.1%, respectively. With respect to
ELISA results, the functional assay sensitivity was determined as 3.0 U/ml
and 3.5 U/ml for IgG to CL and b2 GPI, respectively, and 2.0 U/ml and
2.5 U/ml for IgM to CL and b2 GPI, respectively. Furthermore, ROC curve
analysis revealed the best assay performance for anti-CL IgG antibodies.
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